Phenotypic trait

DGAP-News: KAP AIMS TO ACCELERATE GROWTH AND IS IN ADVANCED NEGOTIATIONS TO ACQUIRE VINYL SPECIALIST HAOGENPLAST

Retrieved on: 
Monday, December 20, 2021
EBITDA, Solution, ILS, Recycling, KAP, Industry, Saskatchewan River Sturgeon Management Board, Acquisition, Printing, Fulda, Construction, Swimming, EUR, Safety, Goal, 3D, TEL, Phenotypic trait, Technology, Retail, Renewable energy

Fulda, 14 December 2021 - KAP AG ("KAP"), a mid-sized industrial holding company listed on the stock exchange, is in advanced negotiations with the owners of HaOgenplast Ltd. ('HaOgenplast') to acquire 100% of the shares in the company in order to strengthen and further expand the flexible films segment.

Key Points: 
  • Fulda, 14 December 2021 - KAP AG ("KAP"), a mid-sized industrial holding company listed on the stock exchange, is in advanced negotiations with the owners of HaOgenplast Ltd. ('HaOgenplast') to acquire 100% of the shares in the company in order to strengthen and further expand the flexible films segment.
  • The planned acquisition is dependent, among other things, on the signing of the purchase agreement by the parties.
  • Founded in 1952, HaOgenplast supplies a worldwide customer base with advanced vinyl films, foils and laminates for applications in the construction, agricultural and industrial sectors.
  • Eckehard Forberich, member and Spokesman of the Management Board of KAP AG: "HaOgenplast is a strong global brand from which we would benefit.

PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH

Retrieved on: 
Tuesday, September 24, 2019
Classical genetics, Phenotype, Phenotypic trait

The Platform has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.

Key Points: 
  • The Platform has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.
  • FibroNest is distributed worldwide on the cloud-based image Visualization and Analysis platform of ViQi, Inc of Santa Barbara, a strategic partner of PharmaNest.
  • Clients and investigators upload their images and receive phenotypic maps and an automated composite phenotypic fibrosis score for a project fee.
  • FibroNest has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.